Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
| Revenue (TTM) | $514.70M |
| Gross Profit (TTM) | $380.31M |
| EBITDA | $40.90M |
| Operating Margin | -174.70% |
| Return on Equity | 0.73% |
| Return on Assets | 2.12% |
| Revenue/Share (TTM) | $4.05 |
| Book Value | $2.36 |
| Price-to-Book | 1.40 |
| Price-to-Sales (TTM) | 0.67 |
| EV/Revenue | 0.895 |
| EV/EBITDA | 11.41 |
| Quarterly Earnings Growth (YoY) | 555.00% |
| Quarterly Revenue Growth (YoY) | -57.10% |
| Shares Outstanding | $128.68M |
| Float | $57.38M |
| % Insiders | 47.46% |
| % Institutions | 49.78% |
Volatility is currently expanding